Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.69 |
| ▸ | HRH1 | P35367 | 1/20 | 0.69 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.68 |
| ▸ | TP53 | P04637 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | THPO | P40225 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | CPT2 | P23786 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propionyl-Carnitine SCHEMBL156850 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Propionyl-Carnitine SCHEMBL994714 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Levocarnitine Propionate SCHEMBL1358528 | 0.98 | MEN1 (0.97) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Levocarnitine Propionate SCHEMBL3005249 | 0.98 | MEN1 (0.97) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Propionyl-Carnitine SCHEMBL1358526 | 0.98 | MEN1 (0.97) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Propionyl-Carnitine SCHEMBL19617435 | 0.95 | MEN1 (0.90) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Propionyl-Carnitine SCHEMBL583770 | 0.94 | MEN1 (0.88) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Propionyl-Carnitine SCHEMBL16781736 | 0.92 | MEN1 (0.85) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Propionyl-Carnitine SCHEMBL527837 | 0.92 | MEN1 (0.85) | MEN1KMT2ACYP2C19RECQLCYP1A2 | |
| Levocarnitine Propionate SCHEMBL16781737 | 0.92 | MEN1 (0.85) | MEN1KMT2ACYP2C19RECQLCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1944 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119421945-B | Maturation medium compositions and methods for human cardiac organoids maturation | 密歇根州立大学董事会 | 2026-05-12 | — | — | CN | claimed |
| EP-4701663-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | claimed |
| CN-119421945-A | Maturation medium compositions and methods for human cardiac organoids maturation | 密歇根州立大学董事会 | 2025-02-11 | — | — | CN | claimed |
| WO-2024264013-A1 | BIOAVAILABILITY ENHANCING IONIC LIQUID FORMULATIONS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-12-26 | — | — | WO | claimed |
| WO-2024222890-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-10-31 | — | — | WO | claimed |
| CN-118777470-A | Application of reagent for detecting biomarker in preparation or construction of early gastric cancer diagnosis or diagnosis-assisting product | 北京大学 | 2024-10-15 | — | — | CN | claimed |
| US-20240325324-A1 | COMPOSITIONS AND METHODS FOR TREATING DRY EYE | Genetic Disease Investigators, LLC | 2024-10-03 | — | — | US | claimed |
| CN-115395108-B | Preparation method and application of aqueous electrolyte containing quaternary ammonium salt type amphoteric ion additive | 中南大学 | 2024-09-10 | — | — | CN | claimed |
| WO-2024083949-A1 | ORAL COMPOSITION, A PROCESS FOR ITS MANUFACTURE AND ITS USE AGAINST SKIN AGING | GENE ACTIVE GMBH (CH) | 2024-04-25 | — | — | WO | claimed |
| US-11896721-B2 | Multiparticulate L-carnitine compositions and related methods | Société des Produits Nestlé S.A. (CH) | 2024-02-13 | — | — | US | claimed |
| WO-1999001126-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ALKANOYL L-CARNITINE IN COMBINATION WITH A STATINE FOR TREATING PATHOLOGIES BROUGHT ABOUT BY AN ALTERED LIPID METABOLISM | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1999-01-14 | — | — | WO | claimed |
| WO-1998043499-A2 | NUTRITIONAL SUPPLEMENT | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 1998-10-08 | — | — | WO | claimed |
| WO-1998041113-A2 | MEDICAL FOOD FOR DIABETICS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1998-09-24 | — | — | WO | claimed |
| US-5811457-A | Therapeutical method for treating chronic arteriosclerosis obliterans | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1998-09-22 | — | — | US | claimed |
| US-5747536-A | ATHERIOSCLEROSIS AND CARDIOVASCULAR DISORDERS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1998-05-05 | — | — | US | claimed |
| EP-0793962-A1 | Medicament containing a carnitine derivative for treating arteriosclerosis obliterans | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1997-09-10 | — | — | EP | claimed |
| EP-0480676-B1 | Acyl carnitine esterase, production thereof and method for analyzing acyl carnitines | ASAHI CHEMICAL IND (JP) | 1996-04-10 | — | — | EP | claimed |
| US-5496821-A | Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1996-03-05 | — | — | US | claimed |
| US-5385829-A | Method of assaying for acyl-L-carnitines and short-chain acyl-carnitines | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1995-01-31 | — | — | US | claimed |
| EP-0480676-A2 | Acyl carnitine esterase, production thereof and method for analyzing acyl carnitines | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1992-04-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11896721-B2 | Multiparticulate L-carnitine compositions and related methods | SLC25A20, CPT1B, CPT1A | MEN1 2117/4885KMT2A 1591/4885CYP2C19 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.